Patents Represented by Attorney, Agent or Law Firm Ronald I. Eisenstein
  • Patent number: 6368813
    Abstract: Compounds and methods are described for producing streptavidin mutants with changed affinities. In particular, modifications to the sequence of the natural streptavidin gene is described to create amino acid substitutions resulting in greater affinity for biotin substitutes than for biotin.
    Type: Grant
    Filed: March 23, 2000
    Date of Patent: April 9, 2002
    Assignee: The Trustees of Boston University
    Inventors: Gabriel O. Reznik, Takeshi Sano, Sandor Vajda, Cassandra Smith, Charles Cantor
  • Patent number: 6306893
    Abstract: An object of the invention is to develop galactose or mannose derivatives of docetaxel, etc. having improved solubility and physiological activity, to alleviate burden imposed on patients and to provide effective therapeutic drug for tumors. The present invention provides taxoid derivatives comprising any of paclitaxel, docetaxel and 10-deacetyl-baccatin III to which galactose or mannose is linked through a spacer, and methods for producing taxoid derivatives comprising reacting paclitaxel, docetaxel or 10-deacetyl-baccatin III with tetrabenzyl acetyloxygalactoside or tetrabenzyl acetyloxymannoside, subjecting the product to debenzylation reaction, and optionally to detriethylsilylation reaction.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: October 23, 2001
    Assignees: Ensuiko Sugar Refining Company, Ltd, Bio Research Corporation of Yokohama, Kaken Pharmaceutical Company, Ltd.
    Inventors: Tadakatsu Mandai, Hiroshi Okumoto, Koji Hara, Katsuhiko Mikuni, Kozo Hara, Yoshinori Tsuchiya, Kosho Nakamura, Teruhiko Umetsu
  • Patent number: 6072036
    Abstract: The present invention relates to a method by which one can target an undesired target molecule or target antigen, preferably a protein. The method comprises the intracellular expression of an antibody capable of binding to the target. A DNA sequence is delivered to a cell, the DNA sequence contains a sufficient number of nucleotides coding for the portion of an antibody capable of binding to the target operably linked to a promoter that will permit expression of the antibody in the cell(s) of interest. The antibody is then expressed intracellularly and binds to the target, thereby disrupting the target from its normal actions.
    Type: Grant
    Filed: April 6, 1999
    Date of Patent: June 6, 2000
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Wayne A. Marasco, William A. Haseltine
  • Patent number: 6051410
    Abstract: Recombinant viral vectors which coexpress heterologous polypeptides capable of assembling into defective nonself-propagating viral particles are disclosed. The viral vectors as well as the viral particles can be used as immunogens and for targeted delivery of heterologous gene products and drugs.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: April 18, 2000
    Assignee: Therion Biologics, Corp.
    Inventors: Gail P. Mazzara, Dennis L. Panicali, Bryan Roberts, Linda R. Gritz, Virginia Stallard, Anna Mahr
  • Patent number: 6033902
    Abstract: A vector comprising an HIV segment and a heterologous gene segment, which produces a replication competent and an infective HIV virus is disclosed. When the heterologous gene is a marker gene, the spread of the virus can be observed in both in vitro and in vivo systems. The use of this vector in establishing methods for screening anti-viral compounds is also disclosed.
    Type: Grant
    Filed: December 8, 1992
    Date of Patent: March 7, 2000
    Assignee: Dana-Farber Cancer Institute
    Inventors: William A. Haseltine, Ernest Terwilliger
  • Patent number: 6017717
    Abstract: The present inventors have now discovered that humans have a gene that encodes a novel protein of the thymosin .beta. family. This novel protein, herein referred to as thymosin .beta.15, has the ability to bind and sequester G-actin, like other members of the thymosin .beta. family, but unlike what is known about other members it also directly regulates cell motility in prostatic carcinoma cells. The present invention is direct to an isolated cDNA encoding the human thymosin .beta.15 gene (SEQ ID NO: 1) and have deduced the amino acid sequence (SEQ ID NO: 2).
    Type: Grant
    Filed: April 29, 1998
    Date of Patent: January 25, 2000
    Assignee: Children's Medical Center Corporation
    Inventors: Bruce R. Zetter, Lere Bao
  • Patent number: 6011000
    Abstract: The invention relates to compositions containing chemical compounds and compositions containing steel factor which stimulate the expression of hemoglobin or globin protein such as embryonic or fetal globin, or the proliferation of hemoglobin expressing and other cells. These compositions can be used to treat or prevent the symptoms associated with anemia, sickle cell diseases, thalassemia and other blood disorders. The invention also relates to methods for administering these compositions to patients and to medical aids for the treatment and prevention of blood and other disorders.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 4, 2000
    Inventors: Susan P. Perrine, Douglas V. Faller
  • Patent number: 6004940
    Abstract: The present invention relates to a method by which one can target an undesired target molecule or target antigen, preferably an endogenous protein. The method comprises the intracellular expression of an antibody capable of binding to the target. A DNA sequence is delivered to a cell, the DNA sequence contains a sufficient number of nucleotides coding for the portion of an antibody capable of binding to the target operably linked to a promoter that will permit expression of the antibody in the cell(s) of interest. The antibody is then expressed intracellularly and binds to the target, thereby disrupting the target from its normal actions.
    Type: Grant
    Filed: December 6, 1994
    Date of Patent: December 21, 1999
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Wayne A. Marasco, Jennifer Richardson
  • Patent number: 6001349
    Abstract: We have discovered that by using a recombinant DNA viral vector, preferably a pox virus vector having at least one insertion site containing a DNA segment encoding the carcinoma self-associated antigen, or a cytotoxic T-cell eliciting epitope thereof, operably linked to a promoter capable of expression in the host, human cytotoxic T-cells specific for the carcinoma self-associated antigens can be produced. The method preferably comprises introducing a sufficient amount of the recombinant pox virus vector into a host to stimulate production of cytotoxic T-cells, and contacting the host with additional antigen at periodic intervals thereafter. The additional antigen may be added by using a second pox virus vector from a different pox genus. In another embodiment, additional antigen is added by contacting the host with antigen. The antigen may be formulated with an adjuvant or in a liposomal formulation. The T-cells can be isolated.
    Type: Grant
    Filed: February 22, 1995
    Date of Patent: December 14, 1999
    Assignees: Therion Biologics Corporation, The United States of America as represented by the Department of Health and Human Services
    Inventors: Dennis L. Panicali, Jeffrey Schlom
  • Patent number: 5981276
    Abstract: Packaging defective and packaging proficient HIV vectors are disclosed. These vectors can be used to establish HIV packaging defective cell lines, and to package desired genes. These cell lines can be used in developing a vaccine, HIV antibodies and as part of a system for gene transfer. The packaging proficient vector can be used to target HIV target cells.
    Type: Grant
    Filed: August 20, 1997
    Date of Patent: November 9, 1999
    Assignee: Dana-Farber Cancer Institute
    Inventors: Joseph G. Sodroski, William A. Haseltine, Mark Poznansky, Andrew Lever
  • Patent number: 5981723
    Abstract: We have discovered a nuclear protein in normal human cells, "retinoblastoma-associated protein 1" ("RBAP-1") that binds directly to the retinoblastoma protein pocket of the underphosphorylated form of the retinoblastoma protein ("RB") and does not bind to phosphorylated RB or to RB with inactivating mutations. The translated RBAP-1 sequence does not resemble other proteins whose sequences are known, and RBAP-1 does not contain a sequence homologous to the transforming element common to viral proteins that bind to the RB pocket. RBAP-1 and the E2F transcription activity have similar DNA-binding specificities and can bind to at least some of the same proteins, such as RB and E4.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 9, 1999
    Assignee: Dana-Farber Cancer Institute
    Inventors: William G. Kaelin, Jr., Erik Flemington, James A. DeCaprio, William Sellers, David M. Livingston
  • Patent number: 5965371
    Abstract: The present invention relates to a method by which one can target an undesired target molecule or target antigen, preferably a protein. The method comprises the intracellular expression of an antibody capable of binding to the target. A DNA sequence is delivered to a cell, the DNA sequence contains a sufficient number of nucleotides coding for the portion of an antibody capable of binding to the target operably linked to a promoter that will permit expression of the antibody in the cell(s) of interest. The antibody is then expressed intracellularly and binds to the target, thereby disrupting the target from its normal actions.
    Type: Grant
    Filed: May 9, 1995
    Date of Patent: October 12, 1999
    Assignee: Dana-Farber Cancer Institute
    Inventors: Wayne A. Marasco, William A. Haseltine
  • Patent number: 5932704
    Abstract: Antibodies capable of binding to the a subunit of the human GM-CSF receptor are described. These antibodies can inhibit the proliferation of cells whose growth is dependent upon the presence of human GM-CSF. Methods of assaying for the human GM-CSF receptor are also disclosed.
    Type: Grant
    Filed: January 25, 1995
    Date of Patent: August 3, 1999
    Assignee: Dana-Farber Cancer Institute
    Inventor: Paul T. Jubinsky
  • Patent number: 5905040
    Abstract: Empty viral capsids, particularly animal parvoviral empty capsids, induce protective antibody response against the virus. The empty viral capsids are obtained by recombinant DNA techniques. Expression vectors are constructed containing structural genes encoding capsid proteins in self assembling form. Eukaryotic transfectants express self-assembled empty viral capsids which can be used to vaccinate against the virus or antigenically related species of the virus.
    Type: Grant
    Filed: February 15, 1991
    Date of Patent: May 18, 1999
    Assignee: Therion Biologics Corporation
    Inventors: Gail P. Mazzara, Antonia T. Destree, Dennis L. Panicali
  • Patent number: 5858726
    Abstract: The invention pertains to self-assembled replication defective hybrid virus-like particles having capsid and membrane glycoproteins from at least two different virus types and method of making same. Recombinant viral vectors as well as the viral particles can be used as immunogens and drug delivery vehicles.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: January 12, 1999
    Assignee: Therion Biologics
    Inventor: Lendon Payne
  • Patent number: 5852186
    Abstract: The present invention is directed to a recombinant human monoclonal antibody which binds to a discontinuous epitope on the HIV gp120 envelope glycoprotien, blocks the binding of gp120 to the CD4 receptor, and neutralizes a broad range of HIV isolates. The present invention also provides the primary nucleotide and deduced amino acid sequences of the rearranged heavy and light chains of the recombinant monoclonal antibody of the present invention, and a method of screening for antibodies which block binding of envelope glycoprotein to the CD4 receptor.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 22, 1998
    Assignees: Dana-Farber Cancer Insitute, New England Deaconess Hospital Corp.
    Inventors: Joseph G. Sodroski, Wayne A. Marasco, Marshall R. Posner, William A. Haseltine
  • Patent number: 5852177
    Abstract: A mutein of basic fibroblast growth factors (bFGF) possesses fibroblast growth promoting activity, growth stimulating activity of capillary endothelial cells and angiogenic activity, has high stability and is low toxicity. And therefore, the present mutein is advantageously used as a healing accelerator for burns etc., a therapeutic drug for thrombosis etc., and a cell cultivation promoter.
    Type: Grant
    Filed: January 24, 1989
    Date of Patent: December 22, 1998
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Masaharu Senoo, Reiko Sasada, Tsutomu Kurokawa, Koichi Igarashi
  • Patent number: 5851829
    Abstract: The present invention relates to a method by which one can target an undesired target molecule or target antigen, preferably a protein. The method comprises the intracellular expression of an antibody capable of binding to the target. A DNA sequence is delivered to a cell, the DNA sequence contains a sufficient number of nucleotides coding for the portion of an antibody capable of binding to the target operably linked to a promoter that will permit expression of the antibody in the cell(s) of interest. The antibody is then expressed intracellularly and binds to the target, thereby disrupting the target from its normal actions.
    Type: Grant
    Filed: March 30, 1995
    Date of Patent: December 22, 1998
    Assignee: Dana-Farber Cancer Institute
    Inventors: Wayne A. Marasco, William A. Haseltine
  • Patent number: 5843737
    Abstract: We have now discovered that eukaryotes, including mammals, have a gene that encodes a multifunctional protein having helicase activity, DNA repair activity, p53 sequestering activity and oncogenetic transformation potential. Enhanced transcripts and expression of this gene in non-testicular cells have a high correlation to disease state in a number of cancers, such as colorectal carcinomas, hereditary cancers resulting from defects in DNA repair pathways, breast cancers, etc. Accordingly, discovering enhanced levels of transcript or gene product in non-testicular tissues can be diagnostic of a predisposition to cancer, and prognostic for a particular cancer.
    Type: Grant
    Filed: December 30, 1994
    Date of Patent: December 1, 1998
    Inventors: Lan Bo Chen, Shideng Bao
  • Patent number: 5804196
    Abstract: Recombinant avipox viral vectors which express heterologous polypeptides capable of assembling into defective nonself-propagating viral particles are disclosed. The recombinant avipox viruses can be used to produce significant amounts of the heterologous polypeptides in avian or non-avian cells. Preferably, the recombinant avipox virus is a fowlpox virus. The viral particles can also be used as immunogens and for targeted delivery of heterologous gene products and drugs.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 8, 1998
    Assignee: Therion Biologics Corporation
    Inventors: Gail P. Mazzara, Dennis L. Panicali, Bryan Roberts, Linda R. Gritz, Virginia Stallard